References - Homocysteine in Protein Structure/Function and Human Disease - page 152

418. Zhang Q, Kelly JW. Cys10 mixed disulfides make transthyretin more amyloidogenic under
mildly acidic conditions. Biochemistry. 2003;42(29):8756-61.
419. Yang C, Gu ZW, Yang M, Gotto Jr AM. Primary structure of apoB-100. Chem Phys Lipids.
1994;67-68:99-104.
420. Zinellu A, Zinellu E, Sotgia S, Formato M, Cherchi GM, Deiana L, et al. Factors affecting
S-homocysteinylation of LDL apoprotein B. Clin Chem. 2006;52(11):2054-9.
421. Zinellu A, Loriga G, Scanu B, Pisanu E, Sanna M, Deiana L, et al. Increased low-density
lipoprotein S-homocysteinylation in chronic kidney disease. Am J Nephrol. 2010;32
(3):242-8.
422. Zinellu A, Sotgia S, Pisanu E, Loriga G, Deiana L, Satta AE, et al. LDL S-homocystei-
nylation decrease in chronic kidney disease patients undergone lipid lowering therapy. Eur J
Pharm Sci. 2012;47(1):117-23.
423. Zinellu A, Sotgia S, Scanu B, Deiana L, Talanas G, Terrosu P, et al. Low density lipoprotein
S-homocysteinylation is increased in acute myocardial infarction patients. Clin Biochem.
2012;45(4-5):359-62.
424. Armstrong VW, Walli AK, Seidel D. Isolation, characterization, and uptake in human
fibroblasts of an apo(a)-free lipoprotein obtained on reduction of lipoprotein(a). J Lipid
Res. 1985;26(11):1314-23.
425. Seed M, Hoppichler F, Reaveley D, McCarthy S, Thompson GR, Boerwinkle E, et al.
Relation of serum lipoprotein(a) concentration and apolipoprotein(a) phenotype to coronary
heart disease in patients with familial hypercholesterolemia. N Engl J Med. 1990;322
(21):1494-9.
426. Wild SH, Fortmann SP, Marcovina SM. A prospective case-control study of lipoprotein(a)
levels and apo(a) size and risk of coronary heart disease in Stanford Five-City Project
participants. Arterioscler Thromb Vasc Biol. 1997;17(2):239-45.
427. Foody JM, Milberg JA, Robinson K, Pearce GL, Jacobsen DW, Sprecher DL. Homocysteine
and lipoprotein(a) interact to increase CAD risk in young men and women. Arterioscler
Thromb Vasc Biol. 2000;20(2):493-9.
428. Herrmann W, Quast S, Ellgass A, Wolter K, Kiessig ST, Molinari E, et al. An increased
serum level of free Apo(a) in renal patients is more striking than that of Lp(a) and is
influenced by homocysteine. Nephron. 2000;85(1):41-9.
429. Smith EB, Cochran S. Factors influencing the accumulation in fibrous plaques of lipid derived
from low density lipoprotein. II. Preferential immobilization of lipoprotein (a) (Lp(a)).
Atherosclerosis. 1990;84(2-3):173-81.
430. Harpel PC, Chang VT, Borth W. Homocysteine and other sulfhydryl compounds enhance the
binding of lipoprotein(a) to fibrin: a potential biochemical link between thrombosis, athero-
genesis, and sulfhydryl compound metabolism. Proc Natl Acad Sci USA. 1992;89
(21):10193-7.
431. Whiteman P, Hutchinson S, Handford PA. Fibrillin-1 misfolding and disease. Antioxid
Redox Signal. 2006;8(3-4):338-46.
432. Hutchinson S, Aplin RT, Webb H, Kettle S, Timmermans J, Boers GH, et al. Molecular
effects of homocysteine on cbEGF domain structure: insights into the pathogenesis of
homocystinuria. J Mol Biol. 2005;346(3):833-44.
433. Hubmacher D, Tiedemann K, Bartels R, Brinckmann J, Vollbrandt T, Batge B, et al.
Modification of the structure and function of fibrillin-1 by homocysteine suggests a potential
pathogenetic mechanism in homocystinuria. J Biol Chem. 2005;280(41):34946-55.
434. Hubmacher D, Cirulis JT, Miao M, Keeley FW, Reinhardt DP. Functional consequences of
homocysteinylation of the elastic fiber proteins fibrillin-1 and tropoelastin. J Biol Chem.
2010;285(2):1188-98.
435. Singh P, Carraher C, Schwarzbauer JE. Assembly of fibronectin extracellular matrix. Annu
Rev Cell Dev Biol. 2010;26:397-419.